Venetoclax Makes Inroads Into More Hematologic Setting
Venetoclax Makes Inroads Into More Hematologic Setting Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention in 2020 for positive reports from phase 3 clinical trials exploring its use sopra acute myeloid leukemia and multiple myeloma. Expanding beyond the chronic lymphocytic leukemia/ small Read More